Publications by authors named "S Mocellin"

Diagnosis of nevoid melanoma (NeM) is often difficult because NeM closely resembles a common nevus clinically and histologically. A retrospective study was conducted on 110 patients diagnosed with and/or treated for primary nevoid melanoma at the Veneto Institute of Oncology and at the University Hospital of Padua from August 1999. Mean Breslow thickness was of 1.

View Article and Find Full Text PDF
Article Synopsis
  • Basal cell carcinomas (BCCs) are common skin cancers that can cause local damage but have a low risk of death; traditional treatments include surgery, radiotherapy, and chemotherapy.
  • Electrochemotherapy (ECT) is a newer treatment that uses electrical stimulation to enhance drug delivery directly into cancer cells, showing promising results for BCC.
  • A case report of a 68-year-old man demonstrated that ECT led to complete recovery and improved quality of life, making it a viable alternative or addition to standard surgical options for BCC treatment.
View Article and Find Full Text PDF

In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM.

View Article and Find Full Text PDF

Background: Atypical Spitz tumor (AST) is an intermediate category among Spitz melanocytic neoplasms. Sentinel node biopsy (SNB) has been proposed in the clinical management of AST patients, but this approach remains the subject of debate. This systematic review aims to summarize the available evidence on SNB procedures in AST patients.

View Article and Find Full Text PDF

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia, bone mineralization disorders with increased risk of fragility fractures, muscle pain, and progressive weakness. TIO has been associated with increased production of the phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) usually by mesenchymal tumors of soft tissue or bone (Phosphaturic Mesenchymal Tumors-PMTs). In rare cases TIO may be observed in association with other malignancies.

View Article and Find Full Text PDF